Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oralgen Grass Pollen in Allergic Rhinoconjunctivitis
NCT00567346Phase 3Completed
- Sponsor
- Artu Biologicals
- Start
- Dec 2006
- Primary completion
- Oct 2007
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 7
01
Overview
A Phase 3 trial of Oralgen Grass Pollen in allergic rhinoconjunctivitis (ARC), sponsored by Artu Biologicals. Started Dec 2006; status: completed.
02
Drugs
Oralgen Grass Pollen
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00567346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00567346.